NASDAQ:RDHL Redhill Biopharma (RDHL) Stock Price, News & Analysis $0.40 -0.01 (-2.62%) As of 11:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Redhill Biopharma Stock (NASDAQ:RDHL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Redhill Biopharma alerts:Sign Up Key Stats Today's Range$0.41▼$0.4350-Day Range$0.42▼$0.9052-Week Range$0.39▼$1.60Volume8,727 shsAverage Volume852,469 shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious conditions. Founded in Israel, the company operated internationally, with activities in the United States and other markets through research, regulatory, commercial and licensing relationships. RedHill’s commercial products included Talicia, a combination therapy approved in the United States for the treatment of Helicobacter pylori infection in adults, and Aemcolo, an extended-release antibiotic approved for certain cases of travelers’ diarrhea caused by noninvasive strains of Escherichia coli. The company also developed investigational therapies for gastrointestinal disorders, inflammatory diseases and infectious illnesses, including candidates such as RHB-104, RHB-102, RHB-107 and opaganib. RedHill subsequently faced financial and operational challenges and pursued strategic transactions involving its commercial products and other assets. Because the company’s operating status and asset ownership have changed over time, historical descriptions of its portfolio may not reflect its current activities.AI Generated. May Contain Errors. Read More Redhill Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreRDHL MarketRank™: 0.92810880829 of 5 starsRedhill Biopharma scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRedhill Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRedhill Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Redhill Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRedhill Biopharma has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.55% of the float of Redhill Biopharma has been sold short.Short Interest Ratio / Days to CoverRedhill Biopharma has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Redhill Biopharma has recently decreased by 39.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRedhill Biopharma does not currently pay a dividend.Dividend GrowthRedhill Biopharma does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.37 News SentimentRedhill Biopharma has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Redhill Biopharma this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Redhill Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders6.81% of the stock of Redhill Biopharma is held by insiders.Percentage Held by Institutions7.20% of the stock of Redhill Biopharma is held by institutions.Read more about Redhill Biopharma's insider trading history. Receive RDHL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redhill Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDHL Stock News HeadlinesRedhill Biopharma (NASDAQ:RDHL) Shares Break Below 200-Day Moving Average - Should You Sell?October 21, 2026 | americanbankingnews.com$2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple MyelomaOctober 19, 2026 | prnewswire.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 27 at 1:00 AM | Digest Publishing (Ad)RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial ResultsSeptember 30, 2026 | prnewswire.comRedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?September 10, 2026 | finance.yahoo.comRedhill Biopharma stock doubles in one session — here's whySeptember 1, 2026 | msn.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®September 1, 2026 | markets.businessinsider.comRedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®September 1, 2026 | prnewswire.comSee More Headlines RDHL Stock Analysis - Frequently Asked Questions How have RDHL shares performed this year? Redhill Biopharma's stock was trading at $1.03 at the beginning of the year. Since then, RDHL stock has decreased by 59.6% and is now trading at $0.4159. How were Redhill Biopharma's earnings last quarter? Redhill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to the consensus estimate of $23.41 million. When did Redhill Biopharma's stock split? Redhill Biopharma shares reverse split before market open on Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Redhill Biopharma? Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Redhill Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Micron Technology (MU) and Tesla (TSLA). Company Calendar Last Earnings11/30/2021Today10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 8 days, RDHL's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RDHL Previous SymbolASX:RDH CIK1553846 Webwww.redhillbio.com Phone972-3541-3131Fax972-3541-3144Employees210Year Founded2009Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick RatioN/A Sales & Book Value Annual Sales$290 thousand Price / Sales12.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.49Miscellaneous Outstanding Shares8,890,000Free Float8,283,000Market Cap$3.60 million OptionableNo Data Beta4.91 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:RDHL) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
